Development of BSA conjugated on modified surface of quercetin- loaded lipid nanocarriers for breast cancer treatment

Kumar, Rahul; Choudhary, Dhiraj Kumar; Debnath, Mita Chatterjee

doi:10.1088/2053-1591/ab6774

Cited by 12 publications

(3 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Taking about particular drug delivery nano-vehicle, they could be of two types: either polymer or lipidic nanoparticles. The lipoidal monomers, depending on the type of phospholipid, could bear varied structural identity, having striking pharmacokinetic profile, modifiable surface, excellent biocompatibility and high loading efficiency [208][209][210][211][212][213]. But, the most detrimental fact concerning them is low encapsulation, speedy release and instability upon long term storage.…”

Section: Single Drug Deliverymentioning

confidence: 99%

Lipid polymer hybrid nanoparticles: a custom-tailored next-generation approach for cancer therapeutics

Gajbhiye,

Salve,

Narwade

et al. 2023

Mol Cancer

View full text Add to dashboard Cite

Lipid-based polymeric nanoparticles are the highly popular carrier systems for cancer drug therapy. But presently, detailed investigations have revealed their flaws as drug delivery carriers. Lipid polymer hybrid nanoparticles (LPHNPs) are advanced core–shell nanoconstructs with a polymeric core region enclosed by a lipidic layer, presumed to be derived from both liposomes and polymeric nanounits. This unique concept is of utmost importance as a combinable drug delivery platform in oncology due to its dual structured character. To add advantage and restrict one’s limitation by other, LPHNPs have been designed so to gain number of advantages such as stability, high loading of cargo, increased biocompatibility, rate-limiting controlled release, and elevated drug half-lives as well as therapeutic effectiveness while minimizing their drawbacks. The outer shell, in particular, can be functionalized in a variety of ways with stimuli-responsive moieties and ligands to provide intelligent holding and for active targeting of antineoplastic medicines, transport of genes, and theragnostic. This review comprehensively provides insight into recent substantial advancements in developing strategies for treating various cancer using LPHNPs. The bioactivity assessment factors have also been highlighted with a discussion of LPHNPs future clinical prospects. Graphical Abstract

show abstract

Section: Single Drug Deliverymentioning

confidence: 99%

Lipid polymer hybrid nanoparticles: a custom-tailored next-generation approach for cancer therapeutics

Gajbhiye,

Salve,

Narwade

et al. 2023

Mol Cancer

View full text Add to dashboard Cite

show abstract

“…The MTX-NLS and MTX-NLPHS were synthesized using a single emulsion solvent evaporation method 25 and a one-step precipitation process 26 , respectively. In the MTX-NLPHS, the aqueous phase was prepared by dissolving 5% dextrose in milli-Q-water.…”

Section: Methodsmentioning

confidence: 99%

Drug Encapsulated Lipid-Polymeric Nanohybrid as a Chemo-therapeutic Platform of Cancer

Kumar¹,

Srivastava²,

Mahapatra³

et al. 2023

Nanotheranostics

View full text Add to dashboard Cite

The focus of this research is to design a bioengineered drug delivery vehicle that is efficient in anti-cancer drug delivery in a controlled manner. The experimental work focuses on constructing a methotrexate-loaded nano lipid polymer system (MTX-NLPHS) that can transport methotrexate (MTX) in MCF-7 cell lines in a controlled manner through endocytosis via phosphatidylcholine. In this experiment, MTX is embedded with polylactic-co-glycolic acid (PLGA) in phosphatidylcholine, which acts as a liposomal framework for regulated drug delivery. Scanning electron microscopy (SEM), Fourier transform infrared spectroscopy (FTIR), X-ray diffraction (XRD), and dynamic light scattering (DLS) were utilized to characterize the developed nanohybrid system. The particle size and encapsulation efficiency of the MTX-NLPHS were found to be 198 ± 8.44 nm and 86.48 ± 0.31 %, respectively, which is suitable for biological applications. The polydispersity index (PDI) and zeta potential of the final system were found to be 0.134 ± 0.048 and -28 ± 3.50 mV, respectively. The lower value of PDI showed the homogenous nature of the particle size, whereas higher negative zeta potential prevented the system from agglomeration. An in vitro release kinetics was conducted to see the release pattern of the system, which took 250 h for 100% drug release This kind of system may carry the drug for a long time in the circulatory system and prevent the drug discharge. Other cell culture assays such as 3-(4, 5-dimethyl thiazolyl-2)-2, 5-diphenyltetrazolium bromide (MTT) and reactive oxygen species (ROS) monitoring were used to see the effect of inducers on the cellular system. MTT assay showed cell toxicity of MTX-NLPHS reduced at the lower concentration of the MTX, however, toxicity increased at the higher concentration of the MTX as compared to free MTX. ROS monitoring c revealed more scavenging of ROS using MTX-NLPHS as compared to free MTX. Confocal microscopy suggested the MTX-NLPHS induced more nuclear elongation with cell shrinkage comparatively.

show abstract

“…Quercetin was used as an anticancer therapeutic, encapsulated within lipid nanocarriers and delivered through the P-glycoprotein receptor by Kumar et al to treat breast cancer. Compared with unloaded quercetin, the quercetin-loaded SLNs demonstrated augmented cytotoxicity in drug-resistant human breast carcinoma cell lines [ 83 ].…”

Section: Natural Bioactive Compounds In Lipid-based Drug Delivery Sys...mentioning

confidence: 99%

Lipid-Based Nanoparticles in Delivering Bioactive Compounds for Improving Therapeutic Efficacy

Patel,

Garala,

Singh

et al. 2024

Pharmaceuticals

View full text Add to dashboard Cite

In recent years, due to their distinctive and adaptable therapeutic effects, many natural bioactive compounds have been commonly used to treat diseases. Their limited solubility, low bioavailability, inadequate gastrointestinal tract stability, high metabolic rate, and shorter duration of action limited their pharmaceutical applications. However, those can be improved using nanotechnology to create various drug delivery systems, including lipid-based nanoparticles, to adjust the compounds’ physicochemical properties and pharmacokinetic profile. Because of the enormous technical advancements made in the fundamental sciences and the physical and chemical manipulation of individual atoms and molecules, the subject of nanotechnology has experienced revolutionary growth. By fabricating certain functionalized particles, nanotechnology opens an innovative horizon in research and development for overcoming restrictions, including traditional medication administration systems. Nanotechnology-driven bioactive compounds are certain to have a high impact and clinical value for current and future uses. Lipid-based nanotechnologies were shown to deliver a range of naturally occurring bioactive compounds with decent entrapment potential and stability, a successfully controlled release, increased bioavailability, and intriguing therapeutic activity. This review outlines bioactive compounds such as paclitaxel, curcumin, rhodomyrtone, quercetin, kaempferol, resveratrol, epigallocatechin-3-gallate, silymarin, and oridonin, fortified within either a natural or synthetic lipid-based drug delivery system based on nanotechnology and their evaluation and clinical considerations.

show abstract

Development of BSA conjugated on modified surface of quercetin- loaded lipid nanocarriers for breast cancer treatment

Cited by 12 publications

References 26 publications

Lipid polymer hybrid nanoparticles: a custom-tailored next-generation approach for cancer therapeutics

Lipid polymer hybrid nanoparticles: a custom-tailored next-generation approach for cancer therapeutics

Drug Encapsulated Lipid-Polymeric Nanohybrid as a Chemo-therapeutic Platform of Cancer

Lipid-Based Nanoparticles in Delivering Bioactive Compounds for Improving Therapeutic Efficacy

Contact Info

Product

Resources

About